Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.4% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
13
users have liked this narrative
8
users have commented on this narrative
50
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
24.2% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
7
users have liked this narrative
0
users have commented on this narrative
18
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.4% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
2
users have commented on this narrative
17
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Cannae Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Capital Redeployment And Digital Shift Will Change Outlook Despite Risks
Key Takeaways Aggressive share buybacks and redeployment into private, tech-driven assets are expected to enhance earnings growth and shareholder value. Focused investments in FinTech, healthcare, and data analytics position Cannae to benefit from digital transformation and long-term sector demand.
View narrative
US$22.00
FV
18.1% undervalued
intrinsic discount
-3.48%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Maravai LifeSciences Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
Restructuring And mRNA Advances Will Boost Global Prospects
Key Takeaways Streamlined operations and cost-saving initiatives aim to restore profitability, stabilize margins, and achieve positive free cash flow. Growth is driven by innovation in biologics safety, expansion of GMP consumables, and global diversification, especially in mRNA therapies and precision medicine.
View narrative
US$4.13
FV
37.7% undervalued
intrinsic discount
2.06%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
4 days ago
author updated this narrative
Alpha and Omega Semiconductor
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Expanding AI And Graphics Computing Demand Will Drive Power Management
Key Takeaways Expanding into higher-margin power management and integrated solutions boosts revenue growth, margin improvement, and strengthens position in high-growth AI and device segments. Capital from joint venture sale enables capacity expansion, technology investment, and M&A, supporting operational efficiency, market share gains, and long-term earnings stability.
View narrative
US$30.67
FV
13.8% undervalued
intrinsic discount
5.04%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
4 days ago
author updated this narrative
Arvinas
AN
AnalystConsensusTarget
Consensus Narrative from 18 Analysts
Precision Therapies Will Meet Demand Despite Clinical And Regulatory Risks
Key Takeaways Advancements in targeted therapies and partnerships position Arvinas to capitalize on precision medicine trends and diversify future revenue streams. Streamlined operations and supportive industry momentum enhance prospects for improved margins and faster approval timelines.
View narrative
US$18.44
FV
61.1% undervalued
intrinsic discount
-22.24%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
4 days ago
author updated this narrative
Delek US Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 12 Analysts
Enterprise Optimization And Midstream Investment Will Strengthen US Refining
Key Takeaways Ongoing operational optimization and infrastructure investments are expected to boost margins, lower costs, and create new earnings streams. Strong industry demand and disciplined capital allocation position the company for enhanced cash flow, shareholder returns, and financial flexibility.
View narrative
US$22.17
FV
3.2% overvalued
intrinsic discount
-1.49%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
4 days ago
author updated this narrative
Ocular Therapeutix
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
Future Drug Approvals Will Expand Retinal Disease Treatments
Key Takeaways Potential market leadership in ophthalmology driven by innovative product launches, data differentiation, and expansion into new high-burden eye disease indications. Accelerated commercialization, diversified revenue streams, and strong financial position provide room for growth and protect against immediate dilution risks.
View narrative
US$17.45
FV
27.7% undervalued
intrinsic discount
50.44%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
4 days ago
author updated this narrative
Olo
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
FreedomPay Integration Will Expand Card Present Solutions
Key Takeaways Expanding Olo Pay with improved card-present processing and leveraging FreedomPay partnership aims to boost revenue growth and enhance gross profit through better payment processing. Strategy focuses on increasing brand adoption of Order, Pay, and Engage suites to drive ARPU growth, improve margins, and enhance profitability with efficient data use.
View narrative
US$10.25
FV
0.5% undervalued
intrinsic discount
17.95%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
8
users have followed this narrative
4 days ago
author updated this narrative
Altice USA
AN
AnalystConsensusTarget
Consensus Narrative from 15 Analysts
Fiber Upgrades And Bundling Will Unlock Future Broadband Opportunities
Key Takeaways Expansion of fiber network and bundling of broadband, mobile, and value-added services are strengthening customer loyalty and driving revenue growth. Operational efficiencies, digitalization, and capital structure improvements are boosting margins, cash flow, and financial flexibility for future investments.
View narrative
US$2.78
FV
16.3% undervalued
intrinsic discount
-2.19%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
4 days ago
author updated this narrative
Arcus Biosciences
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
Phase 3 Trials Will Shape Casdatifan Prospects Despite Regulatory Hurdles
Key Takeaways Arcus Biosciences is focusing on casdatifan's late-stage development, promising significant differentiation and competitive advantage in the RCC market. Strong financial partnerships and a long cash runway ensure sustained R&D investment and potential earnings growth through strategic planning.
View narrative
US$28.36
FV
63.1% undervalued
intrinsic discount
7.68%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
4 days ago
author updated this narrative
Value any company in seconds
Popular companies